[go: up one dir, main page]

DE602005016929D1 - Liganden für den cannabinoidrezeptoren - Google Patents

Liganden für den cannabinoidrezeptoren

Info

Publication number
DE602005016929D1
DE602005016929D1 DE602005016929T DE602005016929T DE602005016929D1 DE 602005016929 D1 DE602005016929 D1 DE 602005016929D1 DE 602005016929 T DE602005016929 T DE 602005016929T DE 602005016929 T DE602005016929 T DE 602005016929T DE 602005016929 D1 DE602005016929 D1 DE 602005016929D1
Authority
DE
Germany
Prior art keywords
ligands
cannabinoid receptors
inflammatory
immunomodulatory
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005016929T
Other languages
English (en)
Inventor
Bandarpalle B Shankar
Eric Gilbert
Razia K Rizvi
Chunli Huang
Joseph A Kozlowski
Stuart Mccombie
Neng-Yang Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602005016929D1 publication Critical patent/DE602005016929D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005016929T 2004-06-22 2005-06-21 Liganden für den cannabinoidrezeptoren Expired - Lifetime DE602005016929D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58183704P 2004-06-22 2004-06-22
PCT/US2005/021870 WO2006002133A1 (en) 2004-06-22 2005-06-21 Cannabinoid receptor ligands

Publications (1)

Publication Number Publication Date
DE602005016929D1 true DE602005016929D1 (de) 2009-11-12

Family

ID=35079285

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016929T Expired - Lifetime DE602005016929D1 (de) 2004-06-22 2005-06-21 Liganden für den cannabinoidrezeptoren

Country Status (10)

Country Link
US (1) US7750158B2 (de)
EP (1) EP1768667B1 (de)
JP (1) JP2008503585A (de)
CN (1) CN101005838A (de)
AT (1) ATE444066T1 (de)
CA (1) CA2571058A1 (de)
DE (1) DE602005016929D1 (de)
ES (1) ES2332416T3 (de)
MX (1) MX2007000015A (de)
WO (1) WO2006002133A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080042135A (ko) * 2005-08-19 2008-05-14 엘란 파마슈티칼스, 인크. 감마 세크레타제 억제제로서의 브릿징된 ｎ­비사이클릭설폰아미도
WO2007136571A1 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Pro-drugs of tertiary alcohols
AU2008204583A1 (en) 2007-01-10 2008-07-17 F. Hoffmann-La Roche Ag Sulfonamide derivatives as chymase inhibitors
EP2131655B1 (de) 2007-03-02 2014-05-07 The University of Tennessee Research Foundation Triaryl-/heteroaromatische cannabinoide und ihre verwendung
CN102056933B (zh) 2008-04-11 2014-09-17 詹森药业有限公司 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
CA2761881C (en) 2009-05-14 2017-04-04 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
EP2621902B1 (de) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexanverbindungen zur behandlung von zns-erkrankungen
GB201103419D0 (de) * 2011-02-28 2011-04-13 Univ Aberdeen
AR090044A1 (es) 2011-12-21 2014-10-15 Novira Therapeutics Inc Agentes antivirales para la hepatitis b
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
PT2997019T (pt) 2013-05-17 2018-11-21 Janssen Sciences Ireland Uc Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (de) 2013-07-25 2018-07-21
EA034448B1 (ru) 2013-10-23 2020-02-10 Янссен Сайенсиз Айрлэнд Юси Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (de) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Kombinationstherapie zur behandlung von hbv-infektionen
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EA201792069A1 (ru) 2015-03-19 2018-04-30 Новира Терапьютикс, Инк. Производные азокана и азонана и способы лечения инфекций гепатита в
CN104898325A (zh) * 2015-05-18 2015-09-09 深圳市华星光电技术有限公司 一种液晶显示面板及装置
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
AU2019216522A1 (en) 2018-02-05 2020-08-27 Alkermes, Inc. Compounds for the treatment of pain
EP3765011A1 (de) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Dosierungsschema für kapsid-assemblierungsmodulator
BR112021015618A2 (pt) 2019-02-22 2021-10-05 Janssen Sciences Ireland Unlimited Company Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
WO2020243415A2 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN112516138B (zh) * 2020-12-15 2022-03-29 中国人民解放军陆军军医大学 化合物yx-2102在制备治疗肺纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
KR19990082330A (ko) * 1996-02-06 1999-11-25 미즈노 마사루 신규 화합물 및 이의 의약 용도
JP2001516361A (ja) * 1997-03-18 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体作動薬
PL369952A1 (en) * 2001-11-14 2005-05-02 Schering Corporation Cannabinoid receptor ligands
EP1680124B1 (de) * 2003-10-14 2017-05-31 Pfizer Products Inc. Bicyclische 3.1.0-derivate als glycin-transporter-hemmer

Also Published As

Publication number Publication date
WO2006002133A1 (en) 2006-01-05
JP2008503585A (ja) 2008-02-07
EP1768667B1 (de) 2009-09-30
ES2332416T3 (es) 2010-02-04
CN101005838A (zh) 2007-07-25
ATE444066T1 (de) 2009-10-15
US20060100228A1 (en) 2006-05-11
CA2571058A1 (en) 2006-01-05
EP1768667A1 (de) 2007-04-04
HK1097189A1 (en) 2007-06-22
MX2007000015A (es) 2007-03-07
US7750158B2 (en) 2010-07-06

Similar Documents

Publication Publication Date Title
DE602005016929D1 (de) Liganden für den cannabinoidrezeptoren
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EA200700902A1 (ru) 3-ариламинопиридиновые производные
ATE517882T1 (de) Chinolinderivate
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
EA200801997A1 (ru) Новые соединения
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
DK1853588T3 (da) Kemiske forbindelser
CY1110900T1 (el) Χημικες ενωσεις
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
ATE384058T1 (de) Thiazolderivate
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
GEP20115222B (en) New pharmaceutical compounds
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
TW200637817A (en) 5-aminoindole derivatives
EA201170344A1 (ru) Азаиндольные ингибиторы iap
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür

Legal Events

Date Code Title Description
8364 No opposition during term of opposition